Evaluation of the clinical efficacy of the use of platelet-rich plasma in the treatment of vitiligo
Yu.G. Melnikova, K.M. Lomonosov, L.G. Gereykhanova
Sechenov University, Moscow
Aim: to study the clinical efficacy and safety of platelet-rich plasma (PRP) injection in the treatment of restricted vitiligo.
Patients and Methods: 68 patients with vitiligo aged from 19 to 59 years (49 women and 19 men) with the duration of the disease from 6 months to 22 years were examined. Patients were divided into 2 groups: group 1 (comparison group) — 36 vitiligo patients, treated with photodynamic therapy; group 2 (primary group) — 32 patients, who received PRP injections as part of complex therapy. To compare laboratory studies, data from 40 healthy donors (control group) were used.
Results: the study showed a similar effectiveness of the use of phototherapy and PRP in the treatment of restricted forms of vitiligo in both methods. It was found that the use of PRP allows to obtain clinical remission (full, pronounced and moderate effect) in 87.5% of cases. Analysis of levels of proinflammatory cytokines showed that the use of this method in the treatment of vitiligo is pathogenetically justified, which was confirmed by a significant decrease in the concentrations of interleukins 1, 8, 10 and tumor necrosis factor α in patients with both groups of blood relative to baseline values. The assessment of the dynamics of vascular endothelial growth factor (VEGF) showed that the level of the indicator was significantly higher than the control level before the start of treatment, then after a treatment in both groups of vitiligo patients there was a significant decrease in the VEGF concentration as compared to the baseline level. It was found that the use of PRP resulted in a significant increase in the level of melanin in 2.1–2.2 times in the foci of the disease, similar was the increase in this parameter in the group of patients who received phototherapy. The absence of undesirable phenomena in both groups of patients during the observation period was noted. It was found that the use of PRP in the treatment of vitiligo is safe, not accompanied by side effects, allergic and toxic reactions.
Conclusions: the method of using platelet-rich plasma in the treatment of vitiligo is clinically effective and safe, as its use makes it possible to obtain clinical remission in 87.5% of patients.
For citation: Melnikova Yu.G., Lomonosov K.M., Gereykhanova L.G. Evaluation of the clinical efficacy of the use of platelet-rich plasma in the treatment of vitiligo // RMJ. Medical Review. 2018. № 5. P. 51–54.
References
1. Бабешко О. А., Ломоносов К. М., Гилядова Н. И. Роль цитокинов в патогенезе витилиго // Российский журнал кожных и венерических болезней. 2012. № 3. С.37–41 [Babeshko O.A., Lomonosov K. M., Gilyadova N. I. Rol’ citokinov v patogeneze vitiligo // Rossijskij zhurnal kozhnyh i venericheskih boleznej. 2012. № 3. S.37–41 (in Russian)].
2. Ломоносов К. М. Окислительный стресс и антиоксидантная терапия при различных заболеваниях кожи // Российский журнал кожных и венерических болезней. 2009. № 2. С.27–30 [Lomonosov K. M. Okislitel’nyj stress i antioksidantnaya terapiya pri razlichnyh zabolevaniyah kozhi // Rossijskij zhurnal kozhnyh i venericheskih boleznej. 2009. № 2. S.27–30 (in Russian)].
3. Esmat S., Hegazy R. A., Shalaby S. et al. Phototherapy and Combination Therapies for Vitiligo // Dermatol. Clin. 2017. Vol. 35. № 2. P.171–192. doi: 10.1016/j.det.2016.11.008
4. Шарафутдинова Л. А., Ломоносов К. М. Современные аспекты топической терапии витилиго // Российский журнал кожных и венерических болезней. 2014. № 5. С.40–45 [Sharafutdinova L.A., Lomonosov K. M. Sovremennye aspekty topicheskoj terapii vitiligo // Rossijskij zhurnal kozhnyh i venericheskih boleznej. 2014. № 5. S.40–45 (in Russian)].
5. Толстов Д. А., Богдан В. Г. Комбинированный тромбоцитарно-фибриновый комплекс и обогащенная тромбоцитами плазма в комплексном лечении трофических язв венозной этиологии // Хирургия. Восточная Европа. 2014. № 3. С.45–56 [Tolstov D.A., Bogdan V. G. Kombinirovannyj trombocitarno-fibrinovyj kompleks i obogashchennaya trombocitami plazma v kompleksnom lechenii troficheskih yazv venoznoj ehtiologii // Hirurgiya. Vostochnaya Evropa. 2014. № 3. S.45–56 (in Russian)].
6. Knezevic N. N., Candido K. D., Desai R., Kaye A. D. Is Platelet-Rich Plasma a Future Therapy in Pain Management? // Med. Clin. North. Am. 2016. Vol. 100. № 1. P.199–217. doi: 10.1111/jocd.12194
7. Marques L. F., Stessuk T., Camargo I. C. et al. Platelet-rich plasma (PRP): methodological aspects and clinical applications // Platelets. 2015. Vol. 26. № 2. P.101–113. doi: 10.3109/09537104.2014.881991
8. Van den Boorn J. G., Jakobs C., Hagen C. et al. Inflammasome-Dependent Induction of Adaptive NK Cell Memory // Immunity. 2016. Vol. 44. № 6. P.1406–1421. doi: 10.1016/j.immuni.2016.05.008
9. Ibrahim Z. A., El-Ashmawy A.A., El-Tatawy R.A., Sallam F. A. The effect of platelet-rich plasma on the outcome of short-term narrowband-ultraviolet B phototherapy in the treatment of vitiligo: a pilot study // J. Cosmet. Dermatol. 2016. Vol. 15. № 2. P.108–116. doi: 10.1111/jocd.12194
10. Abdelghani R., Ahmed N. A., Darwish H. M. Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: A prospective, randomized comparative trial // J. Cosmet. Dermatol. Epub 2017 Aug 20. doi: 10.1111/jocd.12397
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
